Unprecedented Advances in Treating Multiple Myeloma With BCMA-Targeted Agents, Featuring a Patient Perspective

This activity was originally broadcast live at the 2022 Asembia Specialty Pharmacy Summit.

This activity features a Patient Perspective.

Program Description

Though the treatment and management of multiple myeloma (MM) has evolved with introduction of new therapies, a large proportion of patients continue to experience treatment failure or have a short duration of response to treatment. Targeting B-cell maturation antigen (BCMA) has emerged as a potential therapeutic target in the MM treatment landscape, with 2 different FDA-approved modalities currently available and others under investigation. This program will guide specialty and managed care pharmacists involved in the care of patients with MM to make clinical decisions for choice of BCMA-targeted agent based on disease- and patient-specific factors. The discussion will also explore potential adverse effects of BCMA-targeted therapies and the pharmacist’s role in adverse effect monitoring and management. This activity features a Patient Perspective interview, offering pharmacists important insight into the patient’s journey and experience from diagnosis to treatment.

Target audience: Specialty pharmacists, oncology pharmacists, and managed care pharmacists

Type of activity: Application
Release date: May 10, 2022
Expiration date: May 10, 2023

Time to complete activity: 1.5 hours
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the role of BCMA as a therapeutic target for relapsed/refractory multiple myeloma
• Analyze current and emerging clinical data for the treatment of multiple myeloma with BCMA-targeted therapies
• Identify potential adverse effects associated with BCMA-targeted therapies to effectively monitor and manage patients
• Investigate strategies for the cost-effective use of BCMA-targeted therapies in the treatment of multiple myeloma

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-22-226-H01-P. The activity is available for CE credit through May 10, 2023.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Faculty

Sara Moran Smith, PharmD, BCOP, has the following relevant financial relationship with a commercial interest to disclose:

Speakers Bureau for Karyopharm

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, has the following relevant financial relationships with commercial interests to disclose:

Research funding:  AstraZeneca, Janssen

Consultant:  BeiGene

Speakers Bureau:  Pfizer

Pharmacy Times Continuing Education™ Planning Staff: Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Amy Seung, PharmD, BCOP, FHOPA; Dipti Desai, PharmD, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no financial relationships with commercial interests to disclose.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

The content of this activity may include information regarding the use of products that may be inconsistent with, or outside the approved labeling for, these products in the United States. Pharmacists should note that the use of these products outside current approved labeling is considered experimental and are advised to consult the prescribing information for these products.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms